×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVAX – novavax, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVAX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/13
08:00 am
nvax
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
Medium
Report
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
12/12
12:42 pm
nvax
Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report? [Yahoo! Finance]
12/12
08:32 am
nvax
Institutional investors control 53% of Novavax, Inc. (NASDAQ:NVAX) and were rewarded last week after stock increased 6.3% [Yahoo! Finance]
Low
Report
Institutional investors control 53% of Novavax, Inc. (NASDAQ:NVAX) and were rewarded last week after stock increased 6.3% [Yahoo! Finance]
12/11
12:27 pm
nvax
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates [Yahoo! Finance]
Low
Report
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates [Yahoo! Finance]
12/11
09:27 am
nvax
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines [Yahoo! Finance]
Low
Report
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines [Yahoo! Finance]
12/10
12:21 pm
nvax
Novavax, Inc. (NASDAQ: NVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Novavax, Inc. (NASDAQ: NVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
12/10
08:14 am
nvax
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza [Yahoo! Finance]
Medium
Report
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza [Yahoo! Finance]
12/10
08:00 am
nvax
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Medium
Report
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/2
04:52 pm
nvax
Form 4 NOVAVAX INC For: Oct 29 Filed by: Rodgers Richard J
Low
Report
Form 4 NOVAVAX INC For: Oct 29 Filed by: Rodgers Richard J
1/2
04:47 pm
nvax
Form 4 NOVAVAX INC For: Dec 13 Filed by: King Rachel K.
Low
Report
Form 4 NOVAVAX INC For: Dec 13 Filed by: King Rachel K.
1/2
04:44 pm
nvax
Form 4 NOVAVAX INC For: Dec 24 Filed by: YOUNG JAMES F
Low
Report
Form 4 NOVAVAX INC For: Dec 24 Filed by: YOUNG JAMES F
1/2
04:02 pm
nvax
Form 144/A NOVAVAX INC Filed by: YOUNG JAMES F
Low
Report
Form 144/A NOVAVAX INC Filed by: YOUNG JAMES F
12/30
05:27 pm
nvax
Form 8-K NOVAVAX INC For: Dec 30
Low
Report
Form 8-K NOVAVAX INC For: Dec 30
12/26
10:31 am
nvax
Form 144 NOVAVAX INC Filed by: YOUNG JAMES F
Low
Report
Form 144 NOVAVAX INC Filed by: YOUNG JAMES F
12/18
05:25 pm
nvax
Form 8-K NOVAVAX INC For: Dec 12
Low
Report
Form 8-K NOVAVAX INC For: Dec 12
12/13
05:25 pm
nvax
Form 4 NOVAVAX INC For: Dec 11 Filed by: Casey Mark J
Low
Report
Form 4 NOVAVAX INC For: Dec 11 Filed by: Casey Mark J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/14
Novavax, Inc. (NASDAQ: NVAX) had its price target raised by analysts at HC Wainwright from $10.00 to $17.00. They now have a "buy" rating on the stock.
40.5%
5/13 Form 4 NOVAVAX INC For: May 13 Filed by: Glenn Gregory M 30.6%
3/17 Novavax, Inc. (NASDAQ: NVAX) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. They now have a $16.00 price target on the stock, up previously from $6.00. 23.9%
11/27 Novavax, Inc. (NASDAQ: NVAX) is now covered by analysts at B. Riley. They set a "buy" rating and a $12.00 price target on the stock. 21.3%
1/21 Experimental-vaccine stocks jump amid spread of new virus in China [MarketWatch] 19.6%
3/24 Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial 18.8%
4/8 Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May 15.3%
2/26 Novavax Advances Development of Novel COVID-19 Vaccine 14.5%
12/31 Form S-3 NOVAVAX INC 13.7%
6/27 Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities 12.6%
5/13 Form 4 NOVAVAX INC For: May 13 Filed by: Glenn Gregory M 30.6%
3/17 Novavax, Inc. (NASDAQ: NVAX) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. They now have a $16.00 price target on the stock, up previously from $6.00. 23.9%
11/27 Novavax, Inc. (NASDAQ: NVAX) is now covered by analysts at B. Riley. They set a "buy" rating and a $12.00 price target on the stock. 21.3%
1/21 Experimental-vaccine stocks jump amid spread of new virus in China [MarketWatch] 19.6%
3/24 Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial 18.8%
4/8 Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May 15.3%
2/26 Novavax Advances Development of Novel COVID-19 Vaccine 14.5%
12/31 Form S-3 NOVAVAX INC 13.7%
6/27 Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities 12.6%
TOP News Decliners
3/2
Form 8-K NOVAVAX INC For: Mar 02
-28.2%
1/21 Form 424B5 NOVAVAX INC -22.9%
3/10 Epidemic response group ups coronavirus vaccine funding to $23.7 mln [Reuters] -20.5%
3/24 Novavax's stock rockets after late-stage trial for flu treatment achieves primary endpoints [MarketWatch] -18.5%
3/11 Form S-3ASR NOVAVAX INC -17.9%
3/14 Earnings Update: Novavax, Inc. Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance News] -16.3%
1/28 Novavax, Inc. (NASDAQ: NVAX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -12.5%
3/25 Novavax, Inc. (NASDAQ: NVAX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.3%
5/8 Novavax Announces Reverse Stock Split of Common Stock -12.3%
4/21 Is This the Best Coronavirus Stock to Buy Now? [The Motley Fool] -11.2%
1/21 Form 424B5 NOVAVAX INC -22.9%
3/10 Epidemic response group ups coronavirus vaccine funding to $23.7 mln [Reuters] -20.5%
3/24 Novavax's stock rockets after late-stage trial for flu treatment achieves primary endpoints [MarketWatch] -18.5%
3/11 Form S-3ASR NOVAVAX INC -17.9%
3/14 Earnings Update: Novavax, Inc. Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance News] -16.3%
1/28 Novavax, Inc. (NASDAQ: NVAX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -12.5%
3/25 Novavax, Inc. (NASDAQ: NVAX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.3%
5/8 Novavax Announces Reverse Stock Split of Common Stock -12.3%
4/21 Is This the Best Coronavirus Stock to Buy Now? [The Motley Fool] -11.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: